Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates
| Autor: | Daniela Kniepeiss, Silvia Schaffellner, Philipp Stiegler, Florian Iberer, Astrid Fahrleitner-Pammer, Helmut Mueller, Karlheinz Tscheliessnigg, Doris Wagner, Estrella Jakoby |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Hepatitis Viral Human Waiting Lists Hepatitis C virus Hepacivirus medicine.medical_treatment Immunology Liver transplantation medicine.disease_cause Virus Replication Gastroenterology Cohort Studies Recurrence Internal medicine medicine Immunology and Allergy Humans Transaminases Pharmacology Sirolimus biology Hepatitis C Middle Aged Viral Load medicine.disease biology.organism_classification Survival Analysis Liver Transplantation surgical procedures operative Hepatitis C Virus Positive Liver Virus Activation Viral disease Viral load medicine.drug Follow-Up Studies |
| Zdroj: | International immunopharmacology. 10(8) |
| ISSN: | 1878-1705 |
| Popis: | There is in vitro proof that mTOR proteins play a role in protecting HCV infected cells from apoptosis. The aim of this cohort study was to evaluate the effect of sirolimus as an mTOR inhibitor on hepatitis C recurrence in liver transplant recipients. Hepatitis C virus positive patients were followed prospectively regarding transaminases, immunosuppressive target levels, HCV RNA and influence of donor and recipient factors on viral recurrence and survival. Viral recurrence was defined as elevated liver enzymes combined with active hepatitis diagnosed on the basis of increasing viral load and/or biopsy-proven HCV relapse in the transplanted organ. Sixty-seven HCV positive patients were included: 39 received a regimen including sirolimus; 28 patients received calcineurin inhibitors. Sirolimus patients showed a significant decrease in the HCV PCR levels (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect